Commission Implementing Decision (EU) 2025/2344 of 19 November 2025 repealing Implementing Decision (EU) 2024/2930 postponing the expiry date of the approval of dazomet for use in biocidal products of product-type 8 in accordance with Regulation (EU) No 528/2012 of the European Parliament and of the Council (Text with EEA relevance)
Grade B
mapped from publisher markup. A grade says how a document's structure was obtained, not how reliable the law is.
Address https://gelex.eu/eli/EU/decision/2025/2344@2025-11-19/en
THE EUROPEAN COMMISSION,
Having regard to the Treaty on the Functioning of the European Union,
Having regard to Regulation (EU) No 528/2012 of the European Parliament and of the Council of 22 May 2012 concerning the making available on the market and use of biocidal products, and in particular Article 14(5) thereof,
After consulting the Standing Committee on Biocidal Products,
Whereas:
(1) Dazomet was included in Annex I to Directive 98/8/EC of the European Parliament and of the Council as an active substance for use in biocidal products of product-type 8. Pursuant to Article 86 of Regulation (EU) No 528/2012, it was therefore considered approved until 31 July 2022 under that Regulation subject to the conditions set out in Annex I to Directive 98/8/EC.
(2) On 26 January 2021, an application was submitted in accordance with Article 13(1) of Regulation (EU) No 528/2012 for the renewal of the approval of dazomet for use in biocidal products of product-type 8 (the application). The application was evaluated by the competent authority of Belgium.
(3) Pursuant to Commission Implementing Decision (EU) 2021/1289, the expiry date of approval of dazomet for use in biocidal products of product-type 8 was postponed to 31 January 2025. That expiry date was further postponed to 31 July 2026 by Commission Implementing Decision (EU) 2024/2930 in order to allow sufficient time for the examination of the application.
(4) Commission Implementing Regulation (EU) 2025/2345 renewed the approval of dazomet for use in biocidal products of product-type 8, subject to the conditions in the Annex to that Regulation, including the expiry date of approval. Therefore, it is appropriate to repeal Implementing Decision (EU) 2024/2930 postponing the expiry date of the approval of dazomet,
HAS ADOPTED THIS DECISION:
Article 1
Implementing Decision (EU) 2024/2930 is repealed.
Article 2
This Decision shall enter into force on the twentieth day following that of its publication in the Official Journal of the European Union.
Done at Brussels, 19 November 2025. For the Commission The President Ursula von der Leyen